{"id":745756,"date":"2018-03-01T07:00:00","date_gmt":"2018-03-01T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\/"},"modified":"2025-11-07T01:27:27","modified_gmt":"2025-11-07T06:27:27","slug":"merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\/","title":{"rendered":"Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018"},"content":{"rendered":"<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that data from studies of Merck\u2019s robust HIV pipeline,<br \/>\n      including doravirine, a late-stage investigational non-nucleoside<br \/>\n      reverse transcriptase inhibitor (NNRTI), and MK-8591, an investigational<br \/>\n      nucleoside reverse transcriptase translocation inhibitor (NRTTI), a<br \/>\n      \u201cfirst of its kind\u201d mechanism to enter clinical trials, are scheduled to<br \/>\n      be presented at the Conference on Retroviruses and Opportunistic<br \/>\n      Infections (CROI 2018). In addition, Merck scientists will present data<br \/>\n      from experiments investigating the mechanisms of formation and<br \/>\n      maintenance of HIV reservoirs and the impact of HIV persistence in the<br \/>\n      gut on immune recovery during antiretroviral therapy. <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.croiconference.org%2F&amp;esheet=51766713&amp;newsitemid=20180301005497&amp;lan=en-US&amp;anchor=CROI+2018&amp;index=1&amp;md5=1b3605959b5c0b3cef7dd149f5f0cd0b\" rel=\"nofollow\">CROI<br \/>\n      2018<\/a> is taking place in Boston, Massachusetts, from March 4-7, 2018.\n    <\/p>\n<p>\n      \u201cMerck\u2019s commitment to HIV has never wavered, and we are very excited<br \/>\n      about the progress being made in our labs today to both better<br \/>\n      understand HIV and to bring forward the next generation of potential<br \/>\n      treatments,\u201d said Dr. George Hanna, associate vice president, clinical<br \/>\n      research, Merck Research Laboratories.\n    <\/p>\n<p>\n      Presentations include Week 48 subgroup analysis from the pivotal Phase 3<br \/>\n      DRIVE-AHEAD trial evaluating the efficacy and safety of doravirine<br \/>\n      (DOR), lamivudine (3TC) and tenofovir disoproxil fumarate (TDF) in a<br \/>\n      once-daily fixed-dose combination single tablet as a complete regimen<br \/>\n      (DOR\/3TC\/TDF) for the treatment of HIV-1 infection in treatment-na\u00efve<br \/>\n      adults. In addition, results from a Phase 1 study evaluating MK-8591, an<br \/>\n      investigational nucleoside reverse transcriptase translocation inhibitor<br \/>\n      (NRTTI) that potentially inhibits HIV reverse transcriptase through<br \/>\n      multiple mechanisms will be presented in a late breaking abstract<br \/>\n      session.\n    <\/p>\n<p>\n      <span class=\"bwuline\">Merck Abstracts at CROI 2018:<\/span>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract # 491: Similar Efficacy and Safety by Subgroup in<br \/>\n        DRIVE-AHEAD: DOR\/3TC\/TDF versus EFV\/FTC\/TDF<\/i><\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            <i>Chloe Orkin<\/i>\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            <i>Poster presentation, Monday, March 5, 2:30 \u2013 4:00 PM, Poster<br \/>\n            Hall D<\/i>\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract # 89LB: Low Dose MK-8591 Protects Rhesus Macaques Against<br \/>\n        Rectal SHIV Infection<\/i><\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            <i>Martin Markowitz<\/i>\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            <i>Late-breaker oral presentation, Tuesday, March 6, 11:45 AM,<br \/>\n            Ballroom B<\/i>\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract # 26: Multiple Daily Doses of MK-8591 as Low as 0.25 mg<br \/>\n        Are Expected to Suppress HIV<\/i><\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            <i>Randolph P. Matthews<\/i>\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            <i>Oral presentation, Monday, March 5, 11:00 AM, Auditorium<\/i>\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract # 158: CD32+ CD4+ T Cells Are HIV Transcriptionally Active<br \/>\n        Rather Than a Resting Reservoir<\/i><\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            <i>Mohamed Abdel-Mohsen<\/i>\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            <i>Oral presentation, Wednesday, March 7, 5:45 PM, Ballroom A<\/i>\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract # 730: Validation of a Chronic Kidney Disease Risk Score<br \/>\n        in HIV+ Patients in the US<\/i><\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            <i>Anthony Mills<\/i>\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            <i>Poster presentation, Tuesday, March 6, 2:30 \u2013 4:00 PM, Poster<br \/>\n            Hall D<\/i>\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract # 316: A Bispecific Approach for Targeting Negative<br \/>\n        Checkpoint Receptors in HIV-1 Latency<\/i><\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            <i>Daniel Gorman<\/i>\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            <i>Poster presentation, Tuesday, March 6, 2:30 \u2013 4:00 PM, Poster<br \/>\n            Hall A<\/i>\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract # 383: Higher Rectal p24 Levels Correlate with Poor CD4<br \/>\n        Recovery in Treated HIV Infection<\/i><\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            <i>Bonnie J. Howell<\/i>\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            <i>Poster presentation, Wednesday, March 7, 2:30 \u2013 4:00 PM, Poster<br \/>\n            Hall A<\/i>\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract # 376: IL-10 Signaling Is a Key Mechanism of SIV<br \/>\n        Persistence in ART-Treated Rhesus Macaques<\/i><\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            <i>Maria Pino<\/i>\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            <i>Poster presentation, Wednesday, March 7, 2:30 \u2013 4:00 PM, Poster<br \/>\n            Hall A<\/i>\n          <\/li>\n<\/ul>\n<\/li>\n<li class=\"bwlistitemmargb\">\n        <i>Abstract # 393: Blinded Evaluation of Ultrasensitive Assays of HIV<br \/>\n        in Plasma<\/i><\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n            <i>Sheila M. Keating<\/i>\n          <\/li>\n<li class=\"bwlistitemmargb\">\n            <i>Poster presentation, Wednesday, March 7, 2:30 \u2013 4:00 PM, Poster<br \/>\n            Hall A<\/i>\n          <\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>\n      <b>About Doravirine<\/b>\n    <\/p>\n<p>\n      Doravirine (MK-1439, DOR) is an investigational NNRTI being evaluated by<br \/>\n      Merck for the treatment of HIV-1 infection. DOR is being evaluated in<br \/>\n      several ongoing clinical trials both as a once-daily single-entity<br \/>\n      tablet in combination with other antiretroviral agents in a tailored<br \/>\n      regimen, and as a once-daily fixed-dose combination (DOR\/3TC\/TDF) in a<br \/>\n      complete single tablet regimen. Phase 3 trials include DRIVE-FORWARD, a<br \/>\n      trial comparing DOR to once-daily ritonavir-boosted darunavir (DRV+r),<br \/>\n      each administered in combination with emtricitabine (FTC)\/TDF or<br \/>\n      abacavir (ABC)\/3TC, in treatment-na\u00efve adults; DRIVE-AHEAD, a trial<br \/>\n      comparing DOR\/3TC\/TDF to efavirenz (EFV)\/FTC\/TDF in treatment-na\u00efve<br \/>\n      adults; and DRIVE-SHIFT, a trial evaluating a switch to DOR\/3TC\/TDF in<br \/>\n      HIV-1 infected adults who are currently virologically suppressed on<br \/>\n      another antiretroviral regimen. Other ongoing Phase 2 clinical trials<br \/>\n      include an evaluation of DOR\/3TC\/TDF in treatment-na\u00efve adults with<br \/>\n      transmitted resistance to NNRTIs and in people switching from EFV due to<br \/>\n      intolerability.\n    <\/p>\n<p>\n      Earlier this year, the U.S. Food and Drug Administration (FDA) accepted<br \/>\n      for review two New Drug Applications (NDAs) for DOR for the treatment of<br \/>\n      HIV-1 infection in treatment-na\u00efve adults. The submission includes a<br \/>\n      once-daily single-entity tablet in combination with other antiretroviral<br \/>\n      agents in a tailored regimen, and a once-daily fixed-dose combination<br \/>\n      (DOR\/3TC\/TDF) in a complete single tablet regimen. The FDA has set a<br \/>\n      target action date of October 23, 2018, for both applications.\n    <\/p>\n<p>\n      <b>About MK-8591<\/b>\n    <\/p>\n<p>\n      MK-8591 is Merck\u2019s investigational nucleoside reverse transcriptase<br \/>\n      translocation inhibitor (NRTTI) currently being evaluated in clinical<br \/>\n      trials for the treatment of HIV infection. Preclinical evidence<br \/>\n      indicates that MK-8591 inhibits HIV reverse transcriptase through<br \/>\n      multiple mechanisms that are different from any approved anti-HIV<br \/>\n      medicines, including traditional nucleoside reverse transcriptase<br \/>\n      inhibitors (NRTIs). MK-8591 is being evaluated in a 3-part Phase 2b<br \/>\n      dose-ranging trial, DRIVE2SIMPLIFY, a study of MK-8591 in combination<br \/>\n      with doravirine.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world&#8217;s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer&#8217;s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51766713&amp;newsitemid=20180301005497&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=91a83c21f867ab657d81232f8f57183d\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51766713&amp;newsitemid=20180301005497&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=dc08b1f178bff7ed672f1a978c45944d\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51766713&amp;newsitemid=20180301005497&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=eba5557f5397f21e3943f2f8b37a026b\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51766713&amp;newsitemid=20180301005497&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=f7c9eb6422b38f7bb248c5d973721fb0\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51766713&amp;newsitemid=20180301005497&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=853cf5a74ba6b6e5680ec4092529056b\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51766713&amp;newsitemid=20180301005497&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=95103cf8764262400a9cc04c079cce95\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51766713&amp;newsitemid=20180301005497&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=1615420888490cbb31ff67ab5c6ae286\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180301005497r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck <br \/> <span>Media Contacts:<\/span> <br \/>Pamela        Eisele, 267-305-3558<br \/>or<br \/>Carmen de Gourville, 267-305-4195<br \/>or<br \/> <span>Investor        Contacts:<\/span> <br \/>Teri Loxam, 908-740-1986<br \/>or<br \/>Michael        DeCarbo, 908-740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data from studies of Merck\u2019s robust HIV pipeline, including doravirine, a late-stage investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), and MK-8591, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), a \u201cfirst of its kind\u201d mechanism to enter clinical trials, are scheduled to be presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2018). In addition, Merck scientists will present data from experiments investigating the mechanisms of formation and maintenance of HIV reservoirs and the impact of HIV persistence in the gut on immune recovery during antiretroviral therapy. CROI 2018 is taking place in Boston, Massachusetts, from March 4-7, 2018. \u201cMerck\u2019s commitment to HIV has never wavered, and we are very excited about the progress being made in our labs today to both better understand HIV and to bring forward the next<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745756","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018 - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018 - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data from studies of Merck\u2019s robust HIV pipeline, including doravirine, a late-stage investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), and MK-8591, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), a \u201cfirst of its kind\u201d mechanism to enter clinical trials, are scheduled to be presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2018). In addition, Merck scientists will present data from experiments investigating the mechanisms of formation and maintenance of HIV reservoirs and the impact of HIV persistence in the gut on immune recovery during antiretroviral therapy. CROI 2018 is taking place in Boston, Massachusetts, from March 4-7, 2018. \u201cMerck\u2019s commitment to HIV has never wavered, and we are very excited about the progress being made in our labs today to both better understand HIV and to bring forward the next\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\\\/\",\"name\":\"Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018 - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-03-01T07:00:00+00:00\",\"dateModified\":\"2025-11-07T06:27:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018 - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018 - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data from studies of Merck\u2019s robust HIV pipeline, including doravirine, a late-stage investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), and MK-8591, an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), a \u201cfirst of its kind\u201d mechanism to enter clinical trials, are scheduled to be presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2018). In addition, Merck scientists will present data from experiments investigating the mechanisms of formation and maintenance of HIV reservoirs and the impact of HIV persistence in the gut on immune recovery during antiretroviral therapy. CROI 2018 is taking place in Boston, Massachusetts, from March 4-7, 2018. \u201cMerck\u2019s commitment to HIV has never wavered, and we are very excited about the progress being made in our labs today to both better understand HIV and to bring forward the next","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:27+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\/","name":"Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018 - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-03-01T07:00:00+00:00","dateModified":"2025-11-07T06:27:27+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-present-new-data-from-studies-of-investigational-hiv-therapies-doravirine-and-mk-8591-at-croi-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Present New Data from Studies of Investigational HIV Therapies Doravirine and MK-8591 at CROI 2018"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"20f612aa-eb63-4171-a2fd-2c456dd41f51","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745756\/revisions"}],"predecessor-version":[{"id":3675113,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745756\/revisions\/3675113"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745756"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}